Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide Not-Refractory, Dexamethasone+Lenalidomide+Carfilzomib (KRd), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), 1,2,3 prior line of therapy
### Instruction:
Identify the study with the following condition. 
### Input:
Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide Not-Refractory, Dexamethasone+Lenalidomide+Carfilzomib (KRd), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), 1,2,3 prior line of therapy 
### Output:
Popular Name is ASPIRE, Study ID is NCT01080391